Supreme Court says states may bar women on Medicaid from using Planned Parenthood clinics
The court's conservative majority reversed the longstanding rule that said Medicaid patients may obtain medical care from any qualified provider.
By a 6-3 vote, the justices ruled the Medicaid Act does not give patients an 'individual right' to the provider of their choice.
The dispute has turned on abortion. Medicaid is funded by the federal government and the states. For decades, conservative states have argued their funds should not be used in Planned Parenthood clinics because some of those clinics perform abortions.
But until now, the federal government and the courts had said that Medicaid patients have go to any qualified provider for health care.
In dissent, Justice Ketanji Brown Jackson said the decision 'will deprive Medicaid recipients in South Carolina of their only meaningful way of enforcing a right that Congress has expressly granted to them. And, more concretely, it will strip those South Carolinians — and countless other Medicaid recipients around the country — of a deeply personal freedom: the ability to decide who treats us at our most vulnerable.' Justices Sonia Sotomayor and Elena Kagan agreed.
Planned Parenthood clinics provide cancer screenings, birth control medical screenings, pregnancy testing, contraception and other healthcare services.
Congress pays most of the state's costs for Medicaid, and it says 'any individual eligible for medical assistance' may receive care from any provider who is 'qualified to perform the service.'
Lupe Rodríguez, executive director of National Latina Institute for Reproductive Justice, called the decision 'an attack on our healthcare and our freedom to make our own decisions about our bodies and lives. By allowing states to block Medicaid patients from getting care at Planned Parenthood health centers, the Court has chosen politics over people and cruelty over compassion.'
Three years ago, the Supreme Court overturned Roe vs. Wade and ruled states may prohibit nearly all abortions.
Nonetheless, South Carolina continued its legal fight to prevent Medicaid patients from receiving care at Planned Parenthood's clinics in Charleston and Columbia.
Former Gov. Henry McMaster, who issued the ban on Planned Parenthood in 2018, said he did so to protect 'his state's sovereign interests.'
Critics of the move said the state has a severe shortage of doctors and medical personnel who treat low-income patients on Medicaid.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
ITM to Present New Subgroup Analysis Data from the COMPETE Trial at ESMO 2025 and Host an Educational Event for Healthcare Professionals
Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that further data on efficacy, safety and subgroup analysis from its recent Phase 3 COMPETE trial will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress, held from October 17-21, 2025 in Berlin, Germany. ITM will also host an educational event focused on bringing together emerging healthcare professionals across disciplines to engage in scientific discussions about the multidisciplinary dynamics in the theranostics field. Oral Presentation DetailsThe data will be presented by study investigator, Jaume Capdevila, MD, PhD, in an oral presentation titled, 'Efficacy, safety and subgroup analysis of 177Lu-edotreotide vs everolimus in patients with Grade 1 or Grade 2 GEP-NETs: Phase 3 COMPETE trial,' on Saturday, October 18 in the NETs and Endocrine Tumors Proffered Paper Session, from 10:15 am – 11:45 am CEST. Abstract Number: 1706ODate and Time: Saturday, October 18, 2025 from 10:15 am - 11:45 am CESTLocation: Karlsruhe Auditorium - Hall 5.2 Educational Event DetailsITM's educational event, titled 'Precision Meets Practice: A NETworking Experience,' moderated by NET expert Dr. Angela Lamarca, will take place on Sunday, October 19, 2025, from 6:30 pm – 10:00 pm CEST. The medical networking event aims to bring together emerging healthcare professionals from the oncology, nuclear medicine, endocrinology and gastroenterology fields to engage in cross-disciplinary collaboration and discussions around NETs and theranostics. As the event has limited spots, interested physicians may register at the following email address: Date and Time: Sunday, October 19, 2025 from 6:30 pm - 10:00 pm CESTLocation: Berlin, Germany; further details will be shared upon registration ITM's conference presence includes a booth (booth number: 2030) featuring information on the company's innovations in radiopharmaceutical therapy (RPT). About the COMPETE TrialThe COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, SSTR-positive GEP-NET tumors. About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. ITM ContactCorporate CommunicationsKathleen Noonan/Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@ Investor RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@ Attachment 20250819_ITM to Present New Subgroup Analysis Data from the COMPETE Trial at ESMO 2025
Yahoo
28 minutes ago
- Yahoo
Landmark Science announces research to be presented at ISPE 2025
At this year's conference, Landmark Science spotlights real-world evidence's power to drive GLP-1 and Wegovy insights in Medicare and shape regulatory decision-making. LOS ANGELES, Aug. 19, 2025 /PRNewswire/ -- Landmark Science today announced its presence at International Society for Pharmacoepidemiology (ISPE) 2025 annual conference, in collaboration with Innovaccer, set to take place August 22–26 in Washington D.C. Landmark Science's real-world data is featured across five pieces of research to be presented at the conference. The research provides a timely look into patient populations initiating GLP-1 receptor agonists (RAs), offering new insights into the characteristics of Medicare patients initiating these therapies. They also offer a special focus on Medicaid patients initiating Wegovy (semaglutide) for cardiometabolic and cardiovascular risk reduction — an area of growing importance as GLP-1 RAs expand beyond diabetes management. "GLP-1s are on the rise in Medicare — from Type 2 diabetes and obesity to cardiovascular risk reduction, kidney disease, obstructive sleep apnea, and noncirrhotic MASH, indications for GLP-1s have expanded fast. But not a lot is known about utilization in a Medicare population. Real-world evidence is essential in understanding prescribing patterns, patient outcomes, and safety profiles, ultimately guiding optimal care strategies and policy decisions for Medicare beneficiaries," said Shivani Aggarwal, CEO. "The rapid adoption of GLP-1s like semaglutide in cardiometabolic care highlights a critical need for real-world data to inform access, outcomes, and equity," said Puneet Budhiraja - Vice President, Analytics at Humbi AI by Innovaccer. "At ISPE, we're excited to share data that helps stakeholders better understand who is initiating these therapies — and who might be left behind." At this year's ISPE, Landmark epidemiologists are also generating novel methodologies that will shape the future of evidence generation used to support regulatory decision-making. "Our research uncovers nuanced trends and synthesizes them into transparent, evidenced based research—to showcase and drive the utility of real-world evidence in regulatory decision-making," said Shivani Aggarwal. Highlights include: Two poster presentations on Medicare beneficiaries initiating GLP-1 RAs and Wegovy. Two poster presentations underscoring RWE's potential for use in regulatory decision-making. A poster presentation introducing a framework operationalizing regulatory guidelines into key steps for submission success. Schedule a meeting with Landmark Science at ISPE 2025, and learn more about our abstracts and events, including workshops and panels. Follow Landmark Science on LinkedIn for more updates from #ISPE2025. Poster Discussions and Presentations Characteristics of Patients Initiating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (RAs) for Cardiometabolic Risk Reduction in a Medicare Population This study analyzes patient demographics, comorbidities, and outcomes among Medicare beneficiaries initiating any GLP-1 RAs, shedding light on the populations adopting these treatments. - Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-032 Characteristics of Patients Initiating Wegovy (Semaglutide) for Cardiovascular Risk Reduction in a Medicare Population Focusing specifically on Wegovy, this analysis offers a more granular view into who Wegovy initiators are, how they responded, and what happened after Wegovy became an option for cardiovascular protection. - Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-033 Characteristics of RWE used in Regulatory Decision-Making for Marketing Authorization Applications (MAAs) Real-world evidence use is growing but still has mixed acceptance. Here we synthesize emerging patterns into actionable insights for success. - Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-079 Evaluation of Real-World Evidence in Regulatory and HTA Submissions Real-world evidence isn't judged the same everywhere — and the differences matter. We review feedback from regulatory and key HTA bodies to describe the acceptability of RWE in marketing applications. - Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-080 Framework for Real-World Data Used in Regulatory Submissions Discover our framework, which operationalizes regulatory guidelines about real-world data into key steps for submission readiness. - Tuesday Aug 26, 2025 | Hall D | Poster Session C: 12:00 PM – 1:30 PM- Poster Code: C-124 About Landmark Science, Science, Inc. is a premier life science research organization providing real-world evidence and health outcomes research solutions. The company provides a comprehensive suite of services enabling the use of RWE to help patients. Landmark Science's team of experts deliver RWE for clinical program strategy, health economics, commercial, market access, regulators, and payors to meet diverse needs efficiently. Specialties include complex study designs used to support regulatory submissions, therapeutic area expertise, and data landscaping. To learn more, please visit or contact info@ Media Contact:Landmark Sciencemedia@ (424) 535-3011https:// View original content to download multimedia: SOURCE Landmark Science, Inc


Washington Post
34 minutes ago
- Washington Post
Republicans in Congress take a harder line on negotiations with Putin
Some Republicans in Congress are taking a harder line against Russian President Vladimir Putin, even as President Donald Trump appears to have acquiesced to some of the Kremlin's demands as he seeks to negotiate a peace deal in Ukraine.